The news of Susquehanna maintaining a Positive rating on Endava is a good sign for the company, but the lowering of the price target from $112 to $104 may create mixed feelings among investors. This could lead to a neutral short-term impact on the stock price, as the lowered price target might be seen as a slight negative, while the maintained Positive rating is still a positive signal.